Biomaterials for enhancing anti-cancer immunity.

Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody. Adv Mater (2016) 0.76

Surface Coating of Nanoparticles Reduces Background Inflammatory Activity while Increasing Particle Uptake and Delivery. ACS Biomater Sci Eng (2016) 0.76

Targeting immune checkpoints in malignant glioma. Oncotarget (2016) 0.75

Oral delivery of tumor microparticle vaccines activates NOD2 signaling pathway in ileac epithelium rendering potent antitumor T cell immunity. Oncoimmunology (2017) 0.75

Biomaterials Strategies for Generating Therapeutic Immune Responses. Adv Drug Deliv Rev (2017) 0.75

Injectable nanocomposite cryogels for versatile protein drug delivery. Acta Biomater (2017) 0.75

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79

Cancer immunotherapy comes of age. Nature (2011) 12.35

Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60

Neoantigens in cancer immunotherapy. Science (2015) 5.16

Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10

Nanoparticle delivery of cancer drugs. Annu Rev Med (2011) 3.75

Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol (2007) 3.75

Adoptive cell transfer as personalized immunotherapy for human cancer. Science (2015) 3.19

Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97

Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater (2011) 2.71

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 2.52

Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med (2013) 2.15

Infection-mimicking materials to program dendritic cells in situ. Nat Mater (2009) 2.00

Chimeric antigen receptor therapy for cancer. Annu Rev Med (2013) 1.94

T cell exclusion, immune privilege, and the tumor microenvironment. Science (2015) 1.88

Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer (2012) 1.78

Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials (2012) 1.72

Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med (2010) 1.71

In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med (2009) 1.65

Structure-based programming of lymph-node targeting in molecular vaccines. Nature (2014) 1.60

Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater (2012) 1.40

Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A (2011) 1.39

In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci U S A (2011) 1.38

Injectable preformed scaffolds with shape-memory properties. Proc Natl Acad Sci U S A (2012) 1.28

Macroscale delivery systems for molecular and cellular payloads. Nat Mater (2013) 1.25

Therapeutic cancer vaccines. J Clin Invest (2015) 1.23

Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A (2013) 1.20

Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials (2013) 1.13

Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat Mater (2012) 1.12

Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev (2015) 1.10

Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci Transl Med (2013) 1.09

Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res (2014) 1.06

Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res (2013) 1.04

Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res (2014) 1.04

Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy. Angew Chem Int Ed Engl (2011) 1.04

Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest (2015) 1.03

Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials (2011) 1.02

Injectable, porous, and cell-responsive gelatin cryogels. Biomaterials (2013) 0.99

PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution. J Control Release (2011) 0.96

Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol (2014) 0.95

Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. J Control Release (2014) 0.93

The role of the lymphatic system in vaccine trafficking and immune response. Adv Drug Deliv Rev (2011) 0.91

Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines (Basel) (2015) 0.91

Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol (2014) 0.89

Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs in situ. Adv Funct Mater (2013) 0.87

Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity. Mol Pharm (2015) 0.85

In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J Control Release (2013) 0.82

Hydrogels and scaffolds for immunomodulation. Adv Mater (2014) 0.82

Injectable cryogel-based whole-cell cancer vaccines. Nat Commun (2015) 0.80

Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology (2015) 0.79

Engineered Materials for Cancer Immunotherapy. Nano Today (2015) 0.78

Engineering New Approaches to Cancer Vaccines. Cancer Immunol Res (2015) 0.78

Biomaterials for skeletal muscle tissue engineering. Curr Opin Biotechnol (2017) 0.75